{"id":62897,"date":"2026-04-12T11:32:33","date_gmt":"2026-04-12T03:32:33","guid":{"rendered":"https:\/\/flcube.com\/?p=62897"},"modified":"2026-04-12T11:32:34","modified_gmt":"2026-04-12T03:32:34","slug":"sinocelltech-to-raise-rmb-900m-via-private-placement-funds-working-capital-for-biologics-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62897","title":{"rendered":"Sinocelltech to Raise RMB 900M via Private Placement \u2013 Funds Working Capital for Biologics Pipeline"},"content":{"rendered":"\n

Sinocelltech Group Ltd<\/strong> (SHA:\u202f688520<\/a>) announced plans to raise up to RMB 900\u202fmillion (US$132\u202fmillion)<\/strong> through a private placement<\/strong>, with net proceeds designated for working capital replenishment<\/strong> to support ongoing operations and pipeline advancement.<\/p>\n\n\n\n

Financing Overview<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Amount<\/strong><\/td>Up to RMB 900\u202fmillion (~US$132\u202fmillion)<\/td><\/tr>
Structure<\/strong><\/td>Private placement<\/td><\/tr>
Use of Proceeds<\/strong><\/td>Working capital replenishment<\/td><\/tr>
Exchange<\/strong><\/td>Shanghai Stock Exchange (STAR Market)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Commercial Portfolio<\/h2>\n\n\n\n
Category<\/th>Approved\/Authorized Products<\/th><\/tr><\/thead>
Recombinant Proteins<\/strong><\/td>1 product marketed<\/td><\/tr>
Monoclonal Antibodies<\/strong><\/td>4 products approved<\/td><\/tr>
Vaccines<\/strong><\/td>3 products authorized for emergency use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pipeline Development<\/h2>\n\n\n\n